Fulvestrant

Generic Name: Fulvestrant

Brand Names: Faslodex, Fulvestrant Mylan

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₄₇F_₅O_₃S

CAS Number: 129453-61-8

Unique Ingredient Identifier: 22X328QOC4

Background: Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...

Indication: For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.

Associated Conditions: Advanced Breast Cancer, Advanced or Metastatic Breast Cancer

Associated Therapies: -

Clinical Trials

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Phase 1

Recruiting

Conditions: Breast Cancer
Breast Cancer Metastatic
Hormone Receptor Positive Tumor
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Ovarian Cancer
Advanced Cancer
CCNE1 Amplification
Solid Tumor
Metastatic Cancer

Interventions: Drug: INX-315
Drug: Fulvestrant

First Posted Date: 2023-02-21

Last Posted Date: 2024-10-29

Lead Sponsor: Incyclix Bio

Target Recruit Count: 81

Registration Number: NCT05735080

Locations: 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Levine Cancer Institute (LCI)- Atrium Health, Charlotte, North Carolina, United States

and more 4 locations

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer
Premenopausal Breast Cancer
ER Positive Breast Cancer

Interventions: Drug: Goserelin
Drug: Fulvestrant
Drug: Durvalumab
Drug: Capivasertib

First Posted Date: 2023-02-09

Last Posted Date: 2024-06-10

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 42

Registration Number: NCT05720260

Locations: 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Phase 3

Active, not recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: ARV-471
Drug: Fulvestrant

First Posted Date: 2022-12-16

Last Posted Date: 2024-11-22

Lead Sponsor: Pfizer

Target Recruit Count: 624

Registration Number: NCT05654623

Locations: 🇺🇸
Morton Plant Hospital - BayCare Health System, Clearwater, Florida, United States
🇺🇸
3T Radiology LLC, Coconut Creek, Florida, United States
🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States

and more 395 locations

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Inavolisib
Drug: Fulvestrant
Drug: Alpelisib

First Posted Date: 2022-12-12

Last Posted Date: 2024-11-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 400

Registration Number: NCT05646862

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇧🇷
Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 205 locations

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Phase 4

Recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: Alpelisib
Drug: Fulvestrant

First Posted Date: 2022-11-30

Last Posted Date: 2024-10-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05631795

Locations: 🇮🇳
Novartis Investigative Site, New Delhi, India

VS-6766+Abema+Fulv in Met HR+/HER- BC

Phase 1

Recruiting

Conditions: Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer
Hormone Receptor-positive Breast Cancer

Interventions: Drug: VS-6766
Drug: Abemaciclib
Drug: Fulvestrant

First Posted Date: 2022-11-08

Last Posted Date: 2024-06-25

Lead Sponsor: Adrienne G. Waks

Target Recruit Count: 63

Registration Number: NCT05608252

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institite, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Other: Observation
Drug: RP-6306
Drug: Niraparib
Drug: Gemcitabine
Drug: Fulvestrant
Drug: RP-3500

First Posted Date: 2022-11-01

Last Posted Date: 2024-12-18

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 484

Registration Number: NCT05601440

Locations: 🇨🇦
The Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada

and more 7 locations

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Phase 2

Not yet recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab
Drug: pyrotinib
Drug: Dalpiciclib
Drug: fulvestrant

First Posted Date: 2022-10-13

Last Posted Date: 2022-10-13

Lead Sponsor: Fudan University

Target Recruit Count: 126

Registration Number: NCT05577923

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Fulvestrant
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2022-10-12

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 72

Registration Number: NCT05574881

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2

Recruiting

Conditions: Metastatic HER2-Negative Breast Carcinoma
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Recurrent Endometrial Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Malignant Female Reproductive System Neoplasm
Recurrent Ovarian Carcinoma
Unresectable HER2-Negative Breast Carcinoma
Unresectable Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm

First Posted Date: 2022-10-03

Last Posted Date: 2024-12-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2900

Registration Number: NCT05564377

Locations: 🇺🇸
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan, United States
🇺🇸
Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
🇺🇸
Corewell Health Farmington Hills Hospital, Farmington Hills, Michigan, United States

and more 422 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy